On September 11, 2026, the U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) injection for spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. Approval went to Scholar Rock, Inc. The U.S. Prescribing Information classifies the product as a recombinant monoclonal antibody that targets proforms of myostatin.
ISEMBYLD is not a peptide. It is not TB-500, not BPC-157, and not a gray-market research myostatin vial. A COA check can test whether a certificate names a real lab. It cannot turn a storefront listing into Scholar Rock's licensed biologic.
This is the 8:07 Industry News slot for 15 September 2026. It is not a Research Roundup and does not rewrite rusfertide or the other September daily-news slugs.
What happened on September 11
The FDA notice called ISEMBYLD the first SMA therapy that directly targets muscle loss, used alongside existing SMN2-targeted treatments. FDA says SMA affects about 1 in 10,000 live births and is among the leading genetic causes of infant mortality. A faulty SMN1 gene fails to produce a protein needed for motor neuron survival. SMN2-targeted drugs aim to raise functional SMN protein. Patients with more advanced disease still have substantial motor limits.
Scholar Rock's same-day release, fetched from the FinancialContent BusinessWire mirror, uses the same add-on indication. The company said the U.S. launch is underway, product was expected to ship in the coming days, and Scholar Rock Supports is open for insurance, financial assistance, and infusion logistics. Those are commercial statements, not efficacy tables.
FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Scholar Rock said a Rare Pediatric Disease Priority Review Voucher was awarded at approval.
The path was not a first-cycle clean approval. Company reports dated 23 September 2025 described a Complete Response Letter limited to observations at the Catalent Indiana fill-finish facility, not efficacy or safety. Direct HTML for those 2025 pages timed out here. This article notes that manufacturing delay only as background to the later approval.
Kenneth Hobby of Cure SMA called the approval a significant turning point. Investigator Basil Darras, M.D., and CEO David L. Hallal used "new era" and "breakthrough" in the company release. PeptidePrices reports those quotes. It does not adopt them as findings.
What ISEMBYLD is (and is not)
The label and the company release agree on mechanism: ISEMBYLD is a fully human monoclonal IgG4 antibody that binds promyostatin and latent myostatin and inhibits myostatin activation. Apitegromab-mstn is produced in Chinese hamster ovary cells and weighs about 147 kDa. The supplied product is a 150 mg/3 mL (50 mg/mL) single-dose vial (NDC 84717-150-01) from Scholar Rock, Inc., Cambridge, MA (U.S. License No. 2372).
Myostatin is a negative regulator of muscle mass. Blocking its activation is a muscle-directed strategy. It is not SMN replacement, not gene therapy, not TB-500, and not the pentadecapeptide in BPC-157 or the July 2026 PCAC compounding votes.
The labeled use is add-on only. Patients must already be on an SMN2-targeted treatment. In SAPPHIRE that backdrop was nusinersen or risdiplam. Onasemnogene abeparvovec (Zolgensma) was a trial exclusion. The indication does not make ISEMBYLD a monotherapy or a bodybuilding drug.
| Thing | What it is | What 11 September covers |
|---|---|---|
| Myostatin | Endogenous negative regulator of muscle | Class biology, not the drug |
| Apitegromab-mstn (SRK-015) | Fully human IgG4 monoclonal antibody | Binds promyostatin and latent myostatin |
| ISEMBYLD | FDA-approved Scholar Rock brand | SMA add-on in patients 2+ on SMN2 therapy |
| SAPPHIRE (NCT05156320) | Phase 3, randomized, double-blind, placebo-controlled | Efficacy and safety package |
| Nusinersen or risdiplam | SMN2-targeted background | Required in the trial and on the label |
| Research "myostatin" vials | Unapproved catalog listings | Not this approval |
SAPPHIRE design
SAPPHIRE is Study SRK-015-003 / NCT05156320. The registry, queried 15 September 2026 via ClinicalTrials.gov API v2, is COMPLETED. Official title: Phase 3, double-blind, placebo-controlled trial of apitegromab (SRK-015) in later-onset SMA on nusinersen or risdiplam. Actual start is 14 April 2022. Actual primary completion and completion are 18 December 2024. Parallel, randomized, quadruple mask. Actual enrollment is 188.
Patients were 2 to 21 years old, had 5q SMA, were nonambulatory, had later-onset Type 2 or Type 3 SMA diagnosed before SMN2 upregulator therapy, and were already on nusinersen or risdiplam. Randomization was 1:1:1 to 20 mg/kg (twice the recommended dosage), 10 mg/kg (the recommended dosage), or placebo, by intravenous infusion once every 4 weeks for about one year.
The label says all 188 patients were nonambulatory at baseline. Registry inclusion required independent sitting per WHO motor milestones, HFMSE 10 to 45 at screening, at least 10 months of nusinersen (loading plus at least 2 maintenance doses) or at least 6 months of risdiplam, and no invasive ventilation with tracheostomy.
FDA says the primary analysis was in 156 patients aged 2 to 12 years. The label calls that the main efficacy population (n=156). Of those, 53 received at least one 10 mg/kg dose and 50 received placebo. The company release reports n=103 for the 10 mg/kg comparison. That is 53 plus 50. The remaining main-efficacy patients were assigned 20 mg/kg. Ages 13 to 21 were an exploratory registry subpopulation (20 mg/kg or placebo). The label says that older group showed a trend consistent with the 2-to-12 results. That is not a second powered primary.
The primary endpoint was mean change from baseline at 1 year on the Hammersmith Functional Motor Scale Expanded (HFMSE). HFMSE has 33 items and a maximum of 66. A higher score means better motor function. It is not a cure and not independent walking.
| Item | Published figure | Source |
|---|---|---|
| Phase | 3, randomized, double-blind, placebo-controlled, quadruple mask | FDA, PI, NCT, company |
| N randomized | 188 actual | FDA, PI, NCT, company |
| Main efficacy ages | 2 to 12 years (n=156) | FDA, PI |
| 10 mg/kg vs placebo (2 to 12) | 53 vs 50 (company n=103) | PI, company |
| Background | Nusinersen or risdiplam | FDA, PI, NCT |
| Ambulation / types | Nonambulatory; later-onset Types 2 and 3 | PI, NCT, Cure SMA |
| Primary | Change in HFMSE at 1 year | FDA, PI, NCT |
What the numbers show
Primary (ages 2 to 12, recommended dosage). The label reports least-squares mean HFMSE change at 1 year of +1.0 on ISEMBYLD 10 mg/kg versus -1.2 on placebo. The LS mean difference is 2.2 points (95% CI 0.49 to 3.95; nominal p=0.0121). The company release uses the same 2.2-point figure versus SMN2 therapy alone. FDA says treated patients improved at one year while placebo declined.
Key secondary. A 3-point or greater HFMSE gain occurred in 34.2% on 10 mg/kg versus 13.5% on placebo (odds ratio 3.8; 95% CI 1.33 to 10.90; nominal p=0.0125). FDA reprints 34.2% versus 13.5% and says treated patients were more than twice as likely to show a clinically meaningful improvement. Both p-values are labeled nominal. The PI used MMRM for the primary and logistic regression for the responder endpoint, with imputation for missing scores. Ninety-nine percent of the 2-to-12 recommended-dose comparison completed the study.
20 mg/kg. The label says that regimen was assessed and is not recommended because it did not demonstrate additional efficacy.
Safety. Common adverse reactions (at least 20% on ISEMBYLD and more frequent than placebo) are upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. The PI table (N=53 vs N=50) includes those events plus fractures at 9% versus 2%.
The fracture warning is on the label. In Study 1, 5 of 53 patients (9%) on 10 mg/kg and 3 of 53 (6%) on 20 mg/kg had fractures, versus 1 of 50 on placebo (2%). Femur fractures occurred in three ISEMBYLD-treated patients. None discontinued for fractures. In an ongoing open-label extension at 20 mg/kg, fractures occurred in 22 patients (9%), including 5 serious femur fractures. Most had prior low bone density, fractures, or contractures. Some events had no clear fall. Animal studies also showed adverse bone effects.
The company release says the safety database includes more than 500 individuals, some treated more than 7 years, and that 98% of SAPPHIRE participants elected the ONYX extension. Those are company claims, not a second randomized primary.
Serious acute respiratory failure with lower respiratory infection occurred in two patients on 10 mg/kg and one on placebo. Serious pneumonia occurred in three on 10 mg/kg and none on placebo. Mean CPK rose 91 U/L versus 3 U/L by month 12. The label says there are no adequate pregnancy data, monoclonal antibodies can cross the placenta, and animal data showed offspring reproductive and neurobehavioral effects. Lactation data are absent. Contraindications: none.
| Endpoint | ISEMBYLD 10 mg/kg | Placebo |
|---|---|---|
| HFMSE change at 1 year (LS mean) | +1.0 (n=53, ages 2 to 12) | -1.2 (n=50); difference 2.2; nominal p=0.0121 |
| HFMSE gain of 3 or more | 34.2% | 13.5%; OR 3.8; nominal p=0.0125 |
| Fractures (Study 1) | 9% (5/53) | 2% (1/50) |
| Upper respiratory tract infections | 66% | 54% |
| Vomiting | 30% | 16% |
Labeled dosage (not a consumer protocol)
The Prescribing Information lists a recommended dosage of 10 mg/kg once every 4 weeks as an intravenous infusion over about 60 to 120 minutes, at a rate no greater than 150 mL/hour. The product must be diluted in 0.9% Sodium Chloride Injection to 5 mg/mL first. Cure SMA reprints the same interval, window, and rate cap. A missed dose may be given as soon as possible with the schedule restarted 4 weeks later, or skipped to keep the original calendar.
That is labeled infusion information for a licensed biologic. It is not a gray-market protocol. This article does not publish a home reconstitution schedule.
| Setting | Reported assignment | Source |
|---|---|---|
| Recommended dosage | 10 mg/kg IV every 4 weeks | PI, FDA, company, Cure SMA |
| Infusion | About 60 to 120 minutes, rate no greater than 150 mL/hour | PI, Cure SMA |
| Dilution | Required, 0.9% sodium chloride, 5 mg/mL | PI |
| 20 mg/kg | Studied; not recommended (no additional efficacy) | PI |
| Under 2 years | Safety and effectiveness not established | PI |
Research-vendor vials labeled myostatin, apitegromab, SRK-015, or "follistatin" are not ISEMBYLD. See the vendor checklist and the COA verification guide before treating a certificate as the approved product.
What this does not mean
- It is not a peptide. ISEMBYLD is a fully human IgG4 monoclonal antibody. It is not TB-500 and not BPC-157.
- It is not a standalone SMA therapy. The indication requires current SMN2-targeted treatment.
- It is not a cure. SAPPHIRE measured HFMSE over about one year on top of nusinersen or risdiplam.
- A 2.2-point HFMSE difference is not independent walking. It is the LS mean difference versus placebo in nonambulatory patients aged 2 to 12.
- 34.2% is not "most patients gained 3 points." It is the 10 mg/kg responder rate against 13.5% on placebo.
- SAPPHIRE is not the entire SMA census. The trial enrolled nonambulatory Types 2 and 3, ages 2 to 21, on nusinersen or risdiplam, not on Zolgensma.
- 20 mg/kg is not a better dose. The label says it is not recommended.
- This is not a bodybuilding approval. The labeled use is SMA add-on therapy.
- A research storefront is not the approved drug. This approval does not validate gray-market myostatin products.
- The 2025 CRL did not vanish. It delayed the file for manufacturing. It was not an efficacy rejection.
- This is not a rewrite of rusfertide or the PCAC compounding votes.
What did not change
No PeptidePrices peptide page for apitegromab existed on 15 September 2026, and none was created. The live BPC-157 page remains a different product. Prior daily-news slugs stay as written. Approval does not make a myostatin catalog listing equivalent to ISEMBYLD.
Limitations
FDA's notice gives the 156-patient age band and the 34.2% versus 13.5% split without the 2.2-point LS mean or the nominal p-values. This article privileges the PI table. Both p-values are nominal. A later SAPPHIRE paper may add intervals and longer ONYX safety. The 13-to-21 arm is a trend statement. The >500-person safety database and 98% ONYX election are company claims. The 2025 CRL pages timed out; the manufacturing-only characterization is the company's contemporaneous description.
What to watch next
- Payer coverage and site-of-care.
- ONYX follow-up. An extension is not a new randomized primary.
- A full peer-reviewed SAPPHIRE paper.
- Ex-U.S. filings. Global intent is not an EMA decision.
- Storefront copy after launch.
FAQs
Is ISEMBYLD a research peptide?
No. It is a fully human IgG4 monoclonal antibody. It is not TB-500, BPC-157, or a gray-market myostatin vial.
What did FDA approve on September 11, 2026?
ISEMBYLD (apitegromab-mstn) for SMA in adults and pediatric patients 2 years and older who are currently receiving an SMN2-targeted treatment. Approval went to Scholar Rock, Inc.
What did SAPPHIRE show?
In ages 2 to 12, 10 mg/kg (n=53) had a 2.2-point LS mean HFMSE advantage versus placebo (n=50) at one year (nominal p=0.0121). A 3-point or greater gain occurred in 34.2% versus 13.5% (OR 3.8; nominal p=0.0125).
What dose is on the label?
10 mg/kg by intravenous infusion every 4 weeks over about 60 to 120 minutes, rate no greater than 150 mL/hour, diluted first. 20 mg/kg was studied and is not recommended. That is labeled assignment, not a consumer protocol.
Does a myostatin research vial equal ISEMBYLD?
No. A certificate or a catalog name is not Scholar Rock's licensed biologic.
Is ISEMBYLD a cure for SMA?
No. SAPPHIRE tested HFMSE over about one year as an add-on to nusinersen or risdiplam in nonambulatory Types 2 and 3 SMA.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. Nothing here is a dosing protocol or a recommendation to obtain an unapproved product.
Continue your research
- FDA PCAC compounding votes
- What is TB-500
- What is BPC-157
- How to verify a peptide COA
- COA Authenticity Checker
- BPC-157 prices
Sources
- U.S. Food and Drug Administration. FDA approves first therapy to target muscle loss in spinal muscular atrophy. 11 September 2026
- ClinicalTrials.gov NCT05156320. Efficacy and safety of apitegromab in later-onset SMA treated with nusinersen or risdiplam (SAPPHIRE / SRK-015-003)
- Scholar Rock. ISEMBYLD (apitegromab-mstn) U.S. Prescribing Information. Revised September 2026
- Scholar Rock. FDA approval of ISEMBYLD (apitegromab-mstn). BusinessWire via FinancialContent. 11 September 2026
- Cure SMA. ISEMBYLD product page